Fiduxosin

Drug Profile

Fiduxosin

Alternative Names: A 185980.1; ABT 980; Fiduxosin hydrochloride

Latest Information Update: 24 Jan 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Class 3-ring heterocyclic compounds; Pyrimidinones
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 12 Sep 2006 Discontinued - Phase-II for Benign prostatic hyperplasia in USA (unspecified route)
  • 14 May 2003 A preclinical study has been added to the Mens Health pharmacodynamics section
  • 22 Jul 2002 A clinical study has been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top